In:
Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Vol. 38, No. 6 ( 1994-06), p. 1404-1407
Abstract:
To evaluate the potential that multiply resistant human immunodeficiency virus type 1 variants may arise during combination nucleoside and nonnucleoside reverse transcriptase inhibitor therapy, we constructed a series of mutant reverse transcriptase enzymes and viruses that coexpressed various combinations of resistance-associated amino acid substitutions. Substitutions at residues 100 (Leu-- 〉 Ile) and 181 (Tyr-- 〉 Cys), which mediate resistance to the nonnucleosides, suppressed resistance to 3'-azido-3'-deoxythymidine (AZT) when coexpressed with AZT-specific substitutions. However, a number of viral variants that exhibited significantly reduced susceptibilities to both classes of inhibitors were constructed.
Type of Medium:
Online Resource
ISSN:
0066-4804
,
1098-6596
DOI:
10.1128/AAC.38.6.1404
Language:
English
Publisher:
American Society for Microbiology
Publication Date:
1994
detail.hit.zdb_id:
1496156-8
SSG:
12
SSG:
15,3
Permalink